Table 3.
Studies assessing the relationship of FGF23 with outcomes in patients with type 2 diabetes
| Author | N | Follow-up (years) | Age (years) | eGFR (ml/min/1.73 m2) | FGF23 (RU/mL) | Outcome: hazard ratio (95% CI)# |
|---|---|---|---|---|---|---|
| Silva et al. [51] | 107 | 2.8 ± 0.7 | 57.2 ± 7.1 | 52.89 ± 20.15 | 135.0 ± 135.2 | CV mortality: 2.05 (1.01–8.25) |
| Titan et al. [52] | 55 | 2.6 ± 0.8 | 58.4 ± 10.0 | 53.0 ± 20.6 | 92.0 ± 42.9 | Composite endpoint1: 1.09 (1.01–1.16) |
| Tuñón et al. [15•] | 173 | 2.15 ± 0.99 | 62.8 | 73.75 ± 20.84 | 72.2 (56.7–104.9) | Composite endpoint2: 1.27 (1.13–1.43) |
| Yeung et al. [20••] | 310 | 5.8 (3.3–6.5) | 61.5 ± 8.7 | 88.5 ± 14.8 | 84.2 (67.0–117.6) |
All-cause mortality: 2.55 (1.58–4.10) MACE: 1.68 (1.08–2.61) |
| Frimodt et al. [53] | 200 | 6.1 (5.9–6.6) | 59.9 ± 9 | 91.1 ± 18.3 | 71 (52–108) | All-cause mortality: 1.57 (1.11–2.18) |
| Chan et al. [54] | 513 | 6.6 (5.8–7.5) | 55.0 (49.0–62.0) | 91.3 (76.4–111.3) | 112.4 (79.0–165.8) | All-cause mortality: 1.74 (1.44–2.09) |
1Composite endpoint of all-cause mortality, doubling of serum creatinine or requirement for dialysis
2Composite endpoint of acute ischemic events (acute coronary syndrome, stroke or transient ischemic attack), heart failure or death
#Adjusted for potential confounders
Abbreviations: eGFR estimated glomerular filtration rate, FGF23 fibroblast growth factor 23, CI confidence interval, CV cardiovascular, MACE major adverse cardiac event